Literature DB >> 8307048

Use of an immunoglobulin M containing preparation for treatment of two hypogammaglobulinemic patients with persistent Campylobacter jejuni infection.

J C Borleffs1, J F Schellekens, E Brouwer, M Rozenberg-Arska.   

Abstract

This report describes two hypogammaglobulinemic patients with persistent Campylobacter jejuni infections in spite of IgG substitution and antibiotic therapy. Since serum bactericidal activity (SBA) depends on IgM, these patients were each treated with six doses of an IgM-containing immunoglobulin preparation (Pentaglobin) at three-week intervals. During IgG therapy SBA was not seen in either patient. However, one hour following administration of the IgM preparation, SBA increased to 90%. Just before the next dose SBA was still at the 30-70% level. Both patients tolerated the therapy very well and there were no culture-confirmed relapses of Campylobacter jejuni infection. The IgM preparation may therefore be a useful alternative to conventional IgG in the treatment of hypogammaglobulinemic patients with persistent Campylobacter jejuni infection.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8307048     DOI: 10.1007/BF02098467

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  9 in total

1.  IgM-enriched intravenous immunoglobulin therapy in neonatal sepsis.

Authors:  K N Haque; M H Zaidi; H Bahakim
Journal:  Am J Dis Child       Date:  1988-12

Review 2.  Clinical uses of intravenous immunoglobulins.

Authors:  S A Berkman; M L Lee; R P Gale
Journal:  Ann Intern Med       Date:  1990-02-15       Impact factor: 25.391

3.  A rate nephelometer for measuring specific proteins by immunoprecipitin reactions.

Authors:  J C Sternberg
Journal:  Clin Chem       Date:  1977-08       Impact factor: 8.327

Review 4.  Campylobacter enteritis.

Authors:  M J Blaser; L B Reller
Journal:  N Engl J Med       Date:  1981-12-10       Impact factor: 91.245

5.  Immunization with rough mutants of Salmonella minnesota: protective activity of IgM and IgG antibody to the R595 (Re chemotype) mutant.

Authors:  W R McCabe; A DeMaria; H Berberich; M A Johns
Journal:  J Infect Dis       Date:  1988-08       Impact factor: 5.226

6.  Extraintestinal Campylobacter jejuni and Campylobacter coli infections: host factors and strain characteristics.

Authors:  M J Blaser; G P Perez; P F Smith; C Patton; F C Tenover; A J Lastovica; W I Wang
Journal:  J Infect Dis       Date:  1986-03       Impact factor: 5.226

7.  Erysipelas-like skin lesions associated with Campylobacter jejuni septicemia in patients with hypogammaglobulinemia.

Authors:  P J Kerstens; H P Endtz; J F Meis; W J Oyen; R J Koopman; P J van den Broek; J W van der Meer
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1992-09       Impact factor: 3.267

8.  Campylobacter bacteraemia: a report of 10 cases.

Authors:  D W Spelman; N Davidson; N D Buckmaster; W J Spicer; P Ryan
Journal:  Med J Aust       Date:  1986-11-17       Impact factor: 7.738

9.  Susceptibility of Campylobacter isolates to the bactericidal activity of human serum.

Authors:  M J Blaser; P F Smith; P F Kohler
Journal:  J Infect Dis       Date:  1985-02       Impact factor: 5.226

  9 in total
  7 in total

Review 1.  Host-pathogen interactions in Campylobacter infections: the host perspective.

Authors:  Riny Janssen; Karen A Krogfelt; Shaun A Cawthraw; Wilfrid van Pelt; Jaap A Wagenaar; Robert J Owen
Journal:  Clin Microbiol Rev       Date:  2008-07       Impact factor: 26.132

2.  Bactericidal properties of Campylobacter jejuni-specific immunoglobulin M antibodies in commercial immunoglobulin preparations.

Authors:  I B Autenrieth; A Schwarzkopf; J H Ewald; H Karch; R Lissner
Journal:  Antimicrob Agents Chemother       Date:  1995-09       Impact factor: 5.191

3.  Serum bactericidal activity against Helicobacter pylori in patients with hypogammaglobulinaemia.

Authors:  I M E Desar; M van Deuren; T Sprong; J B M J Jansen; F Namavar; C M Vandenbroucke-Grauls; J W M van der Meer
Journal:  Clin Exp Immunol       Date:  2009-06       Impact factor: 4.330

Review 4.  Limited Innovations After More Than 65 Years of Immunoglobulin Replacement Therapy: Potential of IgA- and IgM-Enriched Formulations to Prevent Bacterial Respiratory Tract Infections.

Authors:  Jeroen D Langereis; Michiel van der Flier; Marien I de Jonge
Journal:  Front Immunol       Date:  2018-08-23       Impact factor: 7.561

5.  IgM Augments Complement Bactericidal Activity with Serum from a Patient with a Novel CD79a Mutation.

Authors:  Jeroen D Langereis; Stefanie S Henriet; Saskia Kuipers; Corry M R Weemaes; Mirjam van der Burg; Marien I de Jonge; Michiel van der Flier
Journal:  J Clin Immunol       Date:  2018-01-15       Impact factor: 8.317

6.  Two-sided femoral Campylobacter jejuni osteomyelitis in a patient with acquired hypogammaglobulinemia: a case report.

Authors:  Joost Hartman; Matthijs Westerman; Jiri F P Wagenaar
Journal:  BMC Infect Dis       Date:  2020-03-06       Impact factor: 3.090

7.  Recurrent Campylobacter Bacteremia as the First Manifestation of Hypogammaglobulinemia: a Case Report and Literature Review.

Authors:  Amal A Gharamti; Nour Moukalled; Ali Taher; Zeina A Kanafani
Journal:  Infect Chemother       Date:  2019-12-06
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.